Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | ($11.1M) | ($14.9M) | ($37.2M) | ($37.0M) | ($38.9M) | ($77.2M) | ($66.2M) | ($122.6M) | ($123.4M) | ($79.0M) |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Protagonist Therapeutics, Inc.'s last 12-month Net Income is $170.8M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Protagonist Therapeutics, Inc.'s Net Income growth was N/A. The average annual Net Income growth rates for Protagonist Therapeutics, Inc. have been N/A over the past three years, N/A over the past five years.